Xilio Therapeutics (XLO) Operating Income (2020 - 2026)
Xilio Therapeutics (XLO) posted Operating Income of -$14.1 million for Q1 2026, down 19.23% sequentially from -$11.8 million in Q4 2025, and down 1.88% YoY from -$14.4 million in Q1 2025.
Xilio Therapeutics (XLO) Operating Income (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Operating Income for 7 years, with the latest figure at -$14.1 million in Q1 2026.
- Quarterly Operating Income fell 1.88% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.2 million (up 25.82% YoY) and the FY2025 annual result came in at -$42.0 million, up 30.7% from the prior year.
- Operating Income eased to -$14.1 million in Q1 2026 per XLO's latest filing, from -$11.8 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.9 million in Q3 2025 and troughed at -$24.6 million in Q2 2022.
- A 5-year average of -$16.8 million and a median of -$17.4 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income dropped 28.47% in 2022, then jumped 86.93% in 2025.
- Over 5 years, Operating Income stood at -$23.2 million in 2022, then rose by 21.74% to -$18.1 million in 2023, then advanced by 24.83% to -$13.6 million in 2024, then advanced by 13.16% to -$11.8 million in 2025, then declined by 19.23% to -$14.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$14.1 million, -$11.8 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.49 Mn |
| Mar 31, 2026 | -14.11 Mn |
| Dec 31, 2025 | -11.84 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -14.37 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -13.63 Mn |
| Sep 30, 2024 | -14.76 Mn |
| Jun 30, 2024 | -14.70 Mn |
| Mar 31, 2024 | -17.49 Mn |
| Dec 31, 2023 | -18.13 Mn |
| Sep 30, 2023 | -17.36 Mn |
| Jun 30, 2023 | -20.12 Mn |
| Mar 31, 2023 | -23.53 Mn |
| Dec 31, 2022 | -23.17 Mn |
| Sep 30, 2022 | -20.21 Mn |
| Jun 30, 2022 | -24.55 Mn |
| Mar 31, 2022 | -21.22 Mn |
| Dec 31, 2021 | -19.56 Mn |
| Sep 30, 2021 | -15.96 Mn |